研究单位：[1]Sun Yat-sen University[2]Shanghai Junshi Bioscience Co., Ltd.[3]Beijing Cancer Hospital,Beijing,Beijing,China[4]Chongqing Cancer Hospital,Chongqing,Chongqing,China[5]First People's Hospital of Foshan,Foshan,Guangdong,China[6]Panyu central hospital,Guangzhou,Guangdong,China,510060[7]Cancer Hospital of Guangxi Medical University,Nanning,Guangxi,China[8]Cancer Hospital of Guizhou Medical University,Guiyang,Guizhou,China[9]Hubei Province Cancer Hosiptal,Wuhan,Hubei,China[10]Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China[11]Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China[12]Xiangya Hospital Central South University,Changsha,Hunan,China[13]Jiangxi Province Cancer Hospital,Nanchang,Jiangxi,China[14]Zhejiang Province Cancer Hospital,Hangzhou,Zhejiang,China
This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the de-intensification radical chemoradiotherapy sparing concurrent cisplatin (i.e., toripalimab plus induction chemotherapy followed by radiotherapy alone) in high-risk locoregionally advanced nasopharyngeal carcinoma.
